Fig. 2.

Changes in MDSC frequencies and phenotypes during ipilimumab treatment. a Lin⁻ HLA-DR^−/lo CD15⁺ CD33⁺ CD11b⁺ frequencies significantly decreased after the first ipilimumab dose and remained low at week 9. b CD3⁻ cells cease ARG1 production at week 9 after treatment. Myeloid cells were gated based on CD3 negativity and FSC/SSC characteristics